Monday, June 22, 2015

Health Research: Doctors often misdiagnose zinc deficiency ♦ Scientists identify amino acid that stops seizures in mice ♦ Drug improves cognition in Alzheimer's disease

HIV drug PrEP not linked to greater risk for depression A randomized, placebo-controlled trial of daily oral HIV preexposure prophylaxis (PrEP) in men and transgender women who have sex with men -- reported no link between taking Truvada for oral PrEP and experiencing depression.
Scientists identify amino acid that stops seizures in mice An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study. In a series of experiments, the amino acid D-leucine, found in many foods and certain bacteria, interrupted prolonged seizures, a serious condition known as status epilepticus, and it did so just as effectively as the epilepsy drug diazepam -- the choice of treatment for patients in the throes of convulsions -- but without any of the drug's sedative side effects.
Drug improves cognition in Alzheimer's disease-mouse model in spite of diet Long-term administration of a drug that mimics the hunger-signaling hormone ghrelin protected Alzheimer’s disease-model mice from memory deterioration, despite a high-glycemic-index diet, scientists report.
Doctors often misdiagnose zinc deficiency, unaware of impact of excess zinc Doctors often misdiagnose zinc deficiency, and seem to be unaware of the impact of excess zinc on the body, shows a small audit of clinical practice. Zinc is an essential trace element that is required in daily quantities of 5.5 to 9.5 mg for men, and 4 to 7 mg for women. But zinc supplements are usually only available in formulations of 45 or 50 mg. The US recommended tolerable limit is 40 mg/day
Tamper-resistant pill dispenser aims to stamp out medication misuse You can whack it with a hammer, attack it with a drill, or even stab it with a screwdriver. But try as you might, you won't be able to get into this pill dispenser. Which is exactly the idea.

No comments:

Post a Comment